Status: Not yet recruiting
First-In-Human Study of KHN922 for Injection
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
Participants needed: 276
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Chengdu Kanghong Biotech Co., Ltd.Updated: Apr 9, 2026Locations: 1
Eligibility criteria
Major surgery within 4 weeks or will be expected to require major surgical treat... [+6]